|Go to market news section|
1 May 2013
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
In conformity with DTR 5.6.1R, the Company notifies the market of the following:
As at the date of this announcement, the Company's issued share capital consists of 87,115,828 ordinary shares with a nominal value of 1 pence each ("Ordinary Shares"), with voting rights. The Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of Ordinary Shares with voting rights is 87,115,828.
The above figure of 87,115,828 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.
For further information
Zoe Goulding, Company Secretary
Telephone number: 01606 814730
Dechra is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
|London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.|
|©London Stock Exchange plc. All rights reserved|